Published in J Clin Oncol on October 01, 1986
Transformation of follicular lymphoma. Best Pract Res Clin Haematol (2011) 1.27
Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol (2010) 1.26
Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood (2009) 1.21
DNA flow cytometry of follicular non-Hodgkin's lymphoma. J Clin Pathol (1991) 0.97
The leukaemic phase of non-Hodgkin's lymphoma. J Clin Pathol (1995) 0.94
Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma (2008) 0.89
Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer (1991) 0.89
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer (2001) 0.89
Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer (2006) 0.84
Management of non-Hodgkin's lymphomas. Postgrad Med J (1999) 0.83
Clinically useful monoclonal antibodies in treatment. J Clin Pathol (2002) 0.82
Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res (2014) 0.79
Expanded use of rituximab in the management of non-Hodgkin lymphoma. Onco Targets Ther (2009) 0.78
Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. PLoS One (2015) 0.78
Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leuk Lymphoma (2011) 0.78
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal. Pharmacoeconomics (2013) 0.78
Computed tomography (CT) and ultrasound (US) guided core biopsy in the management of non-Hodgkin's lymphoma. Br J Cancer (1991) 0.77
Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. Am J Hematol (2010) 0.77
Deflazacort in the treatment of haematologic disorders. Eur J Clin Pharmacol (1993) 0.77
CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol (2015) 0.77
Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas. Trans Am Clin Climatol Assoc (2004) 0.77
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. Haematologica (2012) 0.76
The role of autografting in lymphoma. Postgrad Med J (1994) 0.75
A case report of the histologic transformation of primary follicular lymphoma of the duodenum. Medicine (Baltimore) (2014) 0.75
The management of follicular lymphoma. Drugs (1994) 0.75
Fludarabine in the management of malignant lymphomas. Drugs (1994) 0.75
Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. Eur J Nucl Med Mol Imaging (2005) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol (1999) 12.42
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ (1990) 8.90
Mental health of hospital consultants: the effects of stress and satisfaction at work. Lancet (1996) 7.44
Who should measure quality of life, the doctor or the patient? Br J Cancer (1988) 6.32
Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet (1999) 5.58
Burnout and psychiatric disorder among cancer clinicians. Br J Cancer (1995) 4.47
Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet (1991) 4.09
Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ (1994) 3.52
Management of adult acute myelogenous leukaemia. Br Med J (1973) 3.33
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med (1986) 3.27
Updated Kiel classification for lymphomas. Lancet (1988) 3.25
Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol (1992) 3.25
Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol (1975) 3.12
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (1994) 2.94
Women's knowledge and beliefs regarding breast cancer. Br J Cancer (2002) 2.78
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. Int J Cancer (1982) 2.71
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
Who and what influences delayed presentation in breast cancer? Br J Cancer (1998) 2.53
Node negative breast cancer. BMJ (1990) 2.53
The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology (2000) 2.51
Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet (1982) 2.51
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br Med J (1970) 2.51
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J (2000) 2.34
A comparison of nucleolar organizer region staining and Ki-67 immunostaining in non-Hodgkin's lymphoma. Histopathology (1988) 2.30
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders. Lancet (1983) 2.26
Long-term treatment of acromegaly with bromocriptine. Br Med J (1977) 2.18
Expression of human T and B lymphocyte cell-surface markers on leukaemic cells. Lancet (1974) 2.15
The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol (1988) 2.05
[Changed diagnosis and treatment of hepatocellular carcinoma]. Ned Tijdschr Geneeskd (1996) 2.04
Stage I-II pediatric Hodgkin's disease: long-term follow-up demonstrates equivalent survival rates following different management schemes. J Clin Oncol (1990) 2.02
Flood basalts and hot-spot tracks: plume heads and tails. Science (1989) 1.99
Adjuvant low dose radiation in childhood T cell leukaemia/lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG). Br J Cancer (1984) 1.97
Developmentally regulated rearrangement and expression of genes encoding the T cell receptor-T3 complex. Cell (1986) 1.96
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol (1990) 1.94
Acute corneal hydrops in keratoconus. Ophthalmology (1994) 1.90
Prognostic factors for the progression of keratoconus. Ophthalmology (1994) 1.83
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol (2005) 1.80
An orbital period of 0.94 days for the hot-Jupiter planet WASP-18b. Nature (2009) 1.79
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol (2001) 1.79
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia (2011) 1.77
Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy. Br J Cancer (2000) 1.74
A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol (1989) 1.72
Emotional support for cancer patients: what do patients really want? Br J Cancer (1996) 1.72
Inadequacy of iridium implant as sole radiation treatment for operable breast cancer. Eur J Cancer (1996) 1.70
The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol (2000) 1.68
Ten different dietary fibers have significantly different effects on serum and liver lipids of cholesterol-fed rats. J Nutr (1994) 1.68
Infiltrating glomus tumour of lower limb. Br Med J (1972) 1.68
Iron metabolism in patients undergoing regular dialysis therapy. Br Med J (1971) 1.67
Combination chemotherapy in generalized Hodgkin's disease. Br Med J (1970) 1.67
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) (1983) 1.67
Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet (1983) 1.66
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
Variations in the management and survival of women under 50 years with breast cancer in the South East Thames region. Br J Cancer (1996) 1.63
Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification. J Clin Pathol (1987) 1.59
Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol (2003) 1.59
Bleeding oesophageal varices as the presenting feature in primary bilirary cirrhosis. Lancet (1969) 1.59
Central nervous system toxicity of interferon. Br J Cancer (1983) 1.58
A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction. Br J Nutr (2000) 1.56
The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol (1991) 1.55
A mantle plume initiation model for the wrangellia flood basalt and other oceanic plateaus. Science (1991) 1.55
Daunorubicin in acute myelocytic leukaemia. Lancet (1969) 1.54
Combined chemotherapy versus melphalan and prednisolone for treatment of myelomatosis. Lancet (1992) 1.52
Danger lists for the anesthetist. Anaesthesia (1968) 1.52
Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. JAMA (1979) 1.52
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol (1985) 1.51
Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care. Anaesthesia (2005) 1.50
Solitary plasmacytoma. I: Extramedullary soft tissue plasmacytoma. Cancer (1979) 1.50
Bromocriptine treatment of female infertility: report of 13 pregnancies. Br Med J (1975) 1.49
Specificity of limited range of motion variable resistance training. Med Sci Sports Exerc (1989) 1.48
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol (1995) 1.48
High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol (1998) 1.48
Advanced breast cancer: use of resources and cost implications. Br J Cancer (1993) 1.48
Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer (2003) 1.47
Synchrony and causal relations between permian-triassic boundary crises and siberian flood volcanism. Science (1995) 1.46
MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J (1978) 1.46
Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer (1993) 1.45
Rubidomycin in acute leukaemia in adults. Br Med J (1968) 1.45
Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood (1994) 1.44
Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol (2000) 1.43